

Global Chronic Granulomatous Disease (CGD) Treatment Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/GB6B8E7A631BEN.html>

Date: March 2023

Pages: 104

Price: US\$ 3,660.00 (Single User License)

ID: GB6B8E7A631BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Chronic Granulomatous Disease (CGD) Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Chronic Granulomatous Disease (CGD) Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Chronic Granulomatous Disease (CGD) Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Chronic Granulomatous Disease (CGD) Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Chronic Granulomatous Disease (CGD) Treatment players cover Clinigen Group plc, Orchard Therapeutics plc, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG and Lonza, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the "Chronic Granulomatous Disease

“(CGD) Treatment Industry Forecast” looks at past sales and reviews total world Chronic Granulomatous Disease (CGD) Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Granulomatous Disease (CGD) Treatment sales for 2023 through 2029. With Chronic Granulomatous Disease (CGD) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Chronic Granulomatous Disease (CGD) Treatment industry.

This Insight Report provides a comprehensive analysis of the global Chronic Granulomatous Disease (CGD) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chronic Granulomatous Disease (CGD) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Granulomatous Disease (CGD) Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Granulomatous Disease (CGD) Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Granulomatous Disease (CGD) Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Granulomatous Disease (CGD) Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

X-Linked Chronic Granulomatous Disease

Autosomal Recessive Chronic Granulomatous Disease

Segmentation by application

Neutrophil Function Tests

Genetic Testing

Prenatal Testing

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Clinigen Group plc

Orchard Therapeutics plc2032

Horizon Therapeutics plc

ViroMed. Co. Ltd

Bellicum Pharmaceuticals, Inc

Pfizer Inc

Hoffmann-La Roche Ltd

Novartis AG

Lonza

GlaxoSmithKline plc

Eli Lilly and Company

Johnson & Johnson Services, Inc

Merck KGaA

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size 2018-2029
 - 2.1.2 Chronic Granulomatous Disease (CGD) Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Chronic Granulomatous Disease (CGD) Treatment Segment by Type
 - 2.2.1 X-Linked Chronic Granulomatous Disease
 - 2.2.2 Autosomal Recessive Chronic Granulomatous Disease
- 2.3 Chronic Granulomatous Disease (CGD) Treatment Market Size by Type
 - 2.3.1 Chronic Granulomatous Disease (CGD) Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)
- 2.4 Chronic Granulomatous Disease (CGD) Treatment Segment by Application
 - 2.4.1 Neutrophil Function Tests
 - 2.4.2 Genetic Testing
 - 2.4.3 Prenatal Testing
- 2.5 Chronic Granulomatous Disease (CGD) Treatment Market Size by Application
 - 2.5.1 Chronic Granulomatous Disease (CGD) Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

3 CHRONIC GRANULOMATOUS DISEASE (CGD) TREATMENT MARKET SIZE BY

PLAYER

3.1 Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Players

3.1.1 Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Players (2018-2023)

3.1.2 Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Players (2018-2023)

3.2 Global Chronic Granulomatous Disease (CGD) Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 CHRONIC GRANULOMATOUS DISEASE (CGD) TREATMENT BY REGIONS

4.1 Chronic Granulomatous Disease (CGD) Treatment Market Size by Regions (2018-2023)

4.2 Americas Chronic Granulomatous Disease (CGD) Treatment Market Size Growth (2018-2023)

4.3 APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Growth (2018-2023)

4.4 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Growth (2018-2023)

4.5 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2018-2023)

5.2 Americas Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023)

5.3 Americas Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2018-2023)

6.2 APAC Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023)

6.3 APAC Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Chronic Granulomatous Disease (CGD) Treatment by Country (2018-2023)

7.2 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023)

7.3 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment by Region (2018-2023)

8.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023)

8.3 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023)

- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL CHRONIC GRANULOMATOUS DISEASE (CGD) TREATMENT MARKET FORECAST

- 10.1 Global Chronic Granulomatous Disease (CGD) Treatment Forecast by Regions (2024-2029)
 - 10.1.1 Global Chronic Granulomatous Disease (CGD) Treatment Forecast by Regions (2024-2029)
 - 10.1.2 Americas Chronic Granulomatous Disease (CGD) Treatment Forecast
 - 10.1.3 APAC Chronic Granulomatous Disease (CGD) Treatment Forecast
 - 10.1.4 Europe Chronic Granulomatous Disease (CGD) Treatment Forecast
 - 10.1.5 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Forecast
- 10.2 Americas Chronic Granulomatous Disease (CGD) Treatment Forecast by Country (2024-2029)
 - 10.2.1 United States Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.2.2 Canada Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.2.3 Mexico Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.2.4 Brazil Chronic Granulomatous Disease (CGD) Treatment Market Forecast
- 10.3 APAC Chronic Granulomatous Disease (CGD) Treatment Forecast by Region (2024-2029)
 - 10.3.1 China Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.3.2 Japan Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.3.3 Korea Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.3.4 Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market Forecast
 - 10.3.5 India Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.3.6 Australia Chronic Granulomatous Disease (CGD) Treatment Market Forecast
10.4 Europe Chronic Granulomatous Disease (CGD) Treatment Forecast by Country (2024-2029)

10.4.1 Germany Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.4.2 France Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.4.3 UK Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.4.4 Italy Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.4.5 Russia Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.5 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Forecast by Region (2024-2029)

10.5.1 Egypt Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.5.2 South Africa Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.5.3 Israel Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.5.4 Turkey Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.5.5 GCC Countries Chronic Granulomatous Disease (CGD) Treatment Market Forecast

10.6 Global Chronic Granulomatous Disease (CGD) Treatment Forecast by Type (2024-2029)

10.7 Global Chronic Granulomatous Disease (CGD) Treatment Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Clinigen Group plc

11.1.1 Clinigen Group plc Company Information

11.1.2 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product Offered

11.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.1.4 Clinigen Group plc Main Business Overview

11.1.5 Clinigen Group plc Latest Developments

11.2 Orchard Therapeutics plc2032

11.2.1 Orchard Therapeutics plc2032 Company Information

11.2.2 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product Offered

11.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.2.4 Orchard Therapeutics plc2032 Main Business Overview

- 11.2.5 Orchard Therapeutics plc2032 Latest Developments
- 11.3 Horizon Therapeutics plc
 - 11.3.1 Horizon Therapeutics plc Company Information
 - 11.3.2 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.3.4 Horizon Therapeutics plc Main Business Overview
 - 11.3.5 Horizon Therapeutics plc Latest Developments
- 11.4 ViroMed. Co. Ltd
 - 11.4.1 ViroMed. Co. Ltd Company Information
 - 11.4.2 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.4.4 ViroMed. Co. Ltd Main Business Overview
 - 11.4.5 ViroMed. Co. Ltd Latest Developments
- 11.5 Bellicum Pharmaceuticals, Inc
 - 11.5.1 Bellicum Pharmaceuticals, Inc Company Information
 - 11.5.2 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Bellicum Pharmaceuticals, Inc Main Business Overview
 - 11.5.5 Bellicum Pharmaceuticals, Inc Latest Developments
- 11.6 Pfizer Inc
 - 11.6.1 Pfizer Inc Company Information
 - 11.6.2 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Pfizer Inc Main Business Overview
 - 11.6.5 Pfizer Inc Latest Developments
- 11.7 Hoffmann-La Roche Ltd
 - 11.7.1 Hoffmann-La Roche Ltd Company Information
 - 11.7.2 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Hoffmann-La Roche Ltd Main Business Overview

- 11.7.5 Hoffmann-La Roche Ltd Latest Developments
- 11.8 Novartis AG
 - 11.8.1 Novartis AG Company Information
 - 11.8.2 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Novartis AG Main Business Overview
 - 11.8.5 Novartis AG Latest Developments
- 11.9 Lonza
 - 11.9.1 Lonza Company Information
 - 11.9.2 Lonza Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 Lonza Main Business Overview
 - 11.9.5 Lonza Latest Developments
- 11.10 GlaxoSmithKline plc
 - 11.10.1 GlaxoSmithKline plc Company Information
 - 11.10.2 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.10.4 GlaxoSmithKline plc Main Business Overview
 - 11.10.5 GlaxoSmithKline plc Latest Developments
- 11.11 Eli Lilly and Company
 - 11.11.1 Eli Lilly and Company Company Information
 - 11.11.2 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.11.4 Eli Lilly and Company Main Business Overview
 - 11.11.5 Eli Lilly and Company Latest Developments
- 11.12 Johnson & Johnson Services, Inc
 - 11.12.1 Johnson & Johnson Services, Inc Company Information
 - 11.12.2 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.12.4 Johnson & Johnson Services, Inc Main Business Overview

- 11.12.5 Johnson & Johnson Services, Inc Latest Developments
- 11.13 Merck KGaA
 - 11.13.1 Merck KGaA Company Information
 - 11.13.2 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product Offered
 - 11.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.13.4 Merck KGaA Main Business Overview
 - 11.13.5 Merck KGaA Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Chronic Granulomatous Disease (CGD) Treatment Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of X-Linked Chronic Granulomatous Disease

Table 3. Major Players of Autosomal Recessive Chronic Granulomatous Disease

Table 4. Chronic Granulomatous Disease (CGD) Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 6. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Table 7. Chronic Granulomatous Disease (CGD) Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 8. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 9. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Table 10. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Players (2018-2023) & (\$ Millions)

Table 11. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Player (2018-2023)

Table 12. Chronic Granulomatous Disease (CGD) Treatment Key Players Head office and Products Offered

Table 13. Chronic Granulomatous Disease (CGD) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Regions 2018-2023 & (\$ Millions)

Table 17. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Regions (2018-2023)

Table 18. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Country/Region (2018-2023) & (\$ millions)

Table 19. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Country/Region (2018-2023)

Table 20. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size by

Country (2018-2023) & (\$ Millions)

Table 21. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Country (2018-2023)

Table 22. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Table 24. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Table 26. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Region (2018-2023)

Table 28. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Table 30. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Table 32. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Country (2018-2023)

Table 34. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Table 36. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of Chronic Granulomatous Disease (CGD) Treatment

Table 45. Key Market Challenges & Risks of Chronic Granulomatous Disease (CGD) Treatment

Table 46. Key Industry Trends of Chronic Granulomatous Disease (CGD) Treatment

Table 47. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. Clinigen Group plc Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 52. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 53. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. Clinigen Group plc Main Business

Table 55. Clinigen Group plc Latest Developments

Table 56. Orchard Therapeutics plc2032 Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 57. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 58. Orchard Therapeutics plc2032 Main Business

Table 59. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Orchard Therapeutics plc2032 Latest Developments

Table 61. Horizon Therapeutics plc Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

- Table 62. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product Offered
- Table 63. Horizon Therapeutics plc Main Business
- Table 64. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 65. Horizon Therapeutics plc Latest Developments
- Table 66. ViroMed. Co. Ltd Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors
- Table 67. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product Offered
- Table 68. ViroMed. Co. Ltd Main Business
- Table 69. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 70. ViroMed. Co. Ltd Latest Developments
- Table 71. Bellicum Pharmaceuticals, Inc Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors
- Table 72. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product Offered
- Table 73. Bellicum Pharmaceuticals, Inc Main Business
- Table 74. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 75. Bellicum Pharmaceuticals, Inc Latest Developments
- Table 76. Pfizer Inc Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors
- Table 77. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product Offered
- Table 78. Pfizer Inc Main Business
- Table 79. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 80. Pfizer Inc Latest Developments
- Table 81. Hoffmann-La Roche Ltd Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors
- Table 82. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product Offered
- Table 83. Hoffmann-La Roche Ltd Main Business
- Table 84. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 85. Hoffmann-La Roche Ltd Latest Developments
- Table 86. Novartis AG Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 87. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 88. Novartis AG Main Business

Table 89. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Novartis AG Latest Developments

Table 91. Lonza Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 92. Lonza Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 93. Lonza Main Business

Table 94. Lonza Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. Lonza Latest Developments

Table 96. GlaxoSmithKline plc Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 97. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 98. GlaxoSmithKline plc Main Business

Table 99. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. GlaxoSmithKline plc Latest Developments

Table 101. Eli Lilly and Company Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 102. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 103. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 104. Eli Lilly and Company Main Business

Table 105. Eli Lilly and Company Latest Developments

Table 106. Johnson & Johnson Services, Inc Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 107. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 108. Johnson & Johnson Services, Inc Main Business

Table 109. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 110. Johnson & Johnson Services, Inc Latest Developments

Table 111. Merck KGaA Details, Company Type, Chronic Granulomatous Disease (CGD) Treatment Area Served and Its Competitors

Table 112. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product Offered

Table 113. Merck KGaA Main Business

Table 114. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 115. Merck KGaA Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Chronic Granulomatous Disease (CGD) Treatment Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate 2018-2029 (\$ Millions)
- Figure 6. Chronic Granulomatous Disease (CGD) Treatment Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Figure 7. Chronic Granulomatous Disease (CGD) Treatment Sales Market Share by Country/Region (2022)
- Figure 8. Chronic Granulomatous Disease (CGD) Treatment Sales Market Share by Country/Region (2018, 2022 & 2029)
- Figure 9. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type in 2022
- Figure 10. Chronic Granulomatous Disease (CGD) Treatment in Neutrophil Function Tests
- Figure 11. Global Chronic Granulomatous Disease (CGD) Treatment Market: Neutrophil Function Tests (2018-2023) & (\$ Millions)
- Figure 12. Chronic Granulomatous Disease (CGD) Treatment in Genetic Testing
- Figure 13. Global Chronic Granulomatous Disease (CGD) Treatment Market: Genetic Testing (2018-2023) & (\$ Millions)
- Figure 14. Chronic Granulomatous Disease (CGD) Treatment in Prenatal Testing
- Figure 15. Global Chronic Granulomatous Disease (CGD) Treatment Market: Prenatal Testing (2018-2023) & (\$ Millions)
- Figure 16. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application in 2022
- Figure 17. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Player in 2022
- Figure 18. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Regions (2018-2023)
- Figure 19. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size 2018-2023 (\$ Millions)
- Figure 20. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size 2018-2023 (\$ Millions)
- Figure 21. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size

2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Chronic Granulomatous Disease (CGD) Treatment Value Market Share by Country in 2022

Figure 24. United States Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Region in 2022

Figure 29. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type in 2022

Figure 30. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application in 2022

Figure 31. China Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Country in 2022

Figure 38. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Figure 39. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Figure 40. Germany Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 42. UK Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 43. Italy Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 44. Russia Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Chronic Granulomatous Disease (CGD) Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 57. United States Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Chronic Granulomatous Disease (CGD) Treatment Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Chronic Granulomatous Disease (CGD) Treatment Market Size

2024-2029 (\$ Millions)

Figure 61. China Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 62. Japan Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 63. Korea Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 64. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market
Size 2024-2029 (\$ Millions)

Figure 65. India Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 66. Australia Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 67. Germany Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 68. France Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 69. UK Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 70. Italy Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 71. Russia Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 72. Spain Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 73. Egypt Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 74. South Africa Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 75. Israel Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 76. Turkey Chronic Granulomatous Disease (CGD) Treatment Market Size
2024-2029 (\$ Millions)

Figure 77. GCC Countries Chronic Granulomatous Disease (CGD) Treatment Market
Size 2024-2029 (\$ Millions)

Figure 78. Global Chronic Granulomatous Disease (CGD) Treatment Market Size
Market Share Forecast by Type (2024-2029)

Figure 79. Global Chronic Granulomatous Disease (CGD) Treatment Market Size
Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Chronic Granulomatous Disease (CGD) Treatment Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/GB6B8E7A631BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB6B8E7A631BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

